X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The data shows that ARU-1801 offers potential long-term improvement of the primary symptoms seen with SCD without the toxicities and resource utilization associated with fully myeloablative chemotherapies.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
Data demonstrate that ARU-1801 gene therapy may not only be able to reduce severe vaso-occlusive events but also reduce days in hospital for SCD patients, which could provide a clinically meaningful benefit for patients and help reduce health care costs.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
ARU-1801 is designed to address the limitations of current curative allogeneic transplant options, such as low donor availability, the risk of graft-versus-host disease and toxicity from myeloablative chemotherapy.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Under the terms of the agreement, Aldevron will provide good manufacturing practice (GMP)-grade plasmid for Aruvant's upcoming ARU-1801 pivotal trial.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Aldevron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 16, 2021
Details:
The agreement aims to support ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD). Aruvant has chosen Lonza to help develop and manufacture ARU-1801 for its upcoming pivotal trial.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Lonza Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 18, 2021
Details:
Preliminary clinical data from Aruvant's ongoing Phase 1/2 study that demonstrates ARU-1801, administered with only reduced intensity conditioning, can achieve durable reductions in disease burden.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
Data presented at ASH is from the MOMENTUM study, an open label Phase 1/2 clinical trial examining ARU-1801 as a one-time potentially curative gene therapy for individuals with sickle cell disease (SCD).
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
In partnership with SCDAA, Aruvant is working to educate patients about gene therapy, while gaining critical insights from the patient community for its ARU-1801 SCD development program.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: ARU-1801
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sickle Cell Disease Association of America
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 12, 2020
Details:
Aruvant's ARU-1801, received FDA Orphan Drug designation for its efficacy to deliver a highly potent gene payload with enhanced anti-sickling properties, for a Reduced Intensity Conditioning regimen.
Lead Product(s): ARU-1801
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
